Physician profile
Erica M Kretchman
NPI 1003013673
$608,564.15
in general payments reported to CMS, 2019-2025
60 companies · $69K in 2025
The $69K reported for 2025 was more than what 97% of Endocrinology, Diabetes & Metabolism providers received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $57K · 2020: $91K · 2021: $121K · 2022: $137K · 2023: $77K · 2024: $57K · 2025: $69K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $157K · Travel and Lodging: $30K · Food and Beverage: $12K · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $3,150 · Consulting Fee: $413 · Education: $131.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $157,322.50 |
| Travel and Lodging | $29,520.87 |
| Food and Beverage | $12,308.31 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $3,150.00 |
| Consulting Fee | $412.50 |
| Education | $131.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $227,393.83 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $187,703.15 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Astrazeneca Pharmaceuticals Lp | $44,027.40 | 2019-2024 | Farxiga |
| Abbott Laboratories | $32,448.23 | 2019-2025 | Freestyle Libre 3, Proclaim, Freestyle Libre 2 |
| Medtronic Minimed, INC. | $29,789.74 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $25,572.57 | 2019-2025 | Jardiance, Synjardy |
| Medtronic, INC. | $21,012.10 | 2021-2025 | Minimed 630g, Minimed 770g, Minimed 780g |
| Valeritas, INC. | $18,781.11 | 2019 | |
| Mannkind Corporation | $5,425.76 | 2019-2025 | V-Go, Afrezza |
| Dexcom, INC. | $4,126.71 | 2019-2024 | Dexcom G6 Transmitter |
| Zealand Pharma US, INC. | $2,634.25 | 2020-2021 | |
| Corcept Therapeutics | $1,467.73 | 2019-2025 | Korlym |
| Amgen INC. | $1,440.45 | 2019-2025 | Repatha, Tepezza, Evenity |
| Sanofi-Aventis U.S. LLC | $901.99 | 2019-2025 | |
| Xeris Pharmaceuticals, INC. | $582.21 | 2020-2025 | Gvoke Hypopen, Recorlev |
Show all 59 companies
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Erica Kretchman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.